GSK has finalized its acquisition of efimosfermin, a promising new therapeutic for steatotic liver disease. The deal, valued at up to $2 billion, positions GSK to potentially launch a best-in-class treatment for MASH and ALD by 2029, significantly enhancing its hepatology portfolio.
GSK
GSK has halted its Phase III PIVOT-PO trial early after an independent review confirmed tebipenem HBr met its primary efficacy goal in treating complicated urinary tract infections, marking a major step forward for oral antibiotic options.
GSK’s Blenrep combinations have been approved in Japan for treating relapsed or refractory multiple myeloma, following strong Phase III trial results demonstrating improved survival outcomes.
The findings support the increasing amount of data showing that N6LS is a strong antiviral that may be used as part of an all-encompassing antiretroviral treatment plan.
